title: Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
abstract: We performed intravesical instillation of epirubicin in 53 patients with the aim of preventing recurrence of bladder tumors. The patients had undergone transurethral resection of superficial bladder tumors (only transitional-cell carcinoma) within the preceding week, between January of 1990 and July of 1991. Recurrence was found in 11.3% (6/53) of cases during follow-up periods lasting from 1 to 20 months. Side effects occurred in 5.7% (3/53) of the patients. The cumulative nonrecurrence rate was 96.0% for a follow-up period of 6 months and 78.4% for 12 months. The results of this study suggest that intravesical instillation of epirubicin is very useful as adjuvant therapy after transurethral resection of superficial bladder tumors.
authors.affiliation: Division of Urology, San-in Rosai Hospital, Tottori, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Watanabe
authors.forename: I
authors.initials: I
authors.lastname: Miyagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Higasibori
authors.forename: T
authors.initials: T
authors.lastname: Nakahara
authors.forename: F
authors.initials: F
authors.lastname: Sumi
authors.forename: G
authors.initials: G
authors.lastname: Ishida
authors.forename: B
authors.initials: B
authors.lastname: Abe
authors.forename: A
authors.initials: A
authors.lastname: Inoue
authors.forename: N
authors.initials: N
authors.lastname: Hanamoto
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery
chemical_list: D015251:Epirubicin